{"groups":[{"description":"Patients receive MLN8237 (alisertib) PO BID on days 1-7. Treatment repeats every 21 days for 17 courses in the absence of disease progression or unacceptable toxicity","id":"FG000","title":"MLN8237"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Ineligible"},{"reasons":[{"groupId":"FG000","numSubjects":"6"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"20"}],"type":"Progression/relapse"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"5"}],"type":"Other reason not protocol specified"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"42"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"37"}],"type":"Eligible and Treated"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"40"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}